1-甲基-1-苯基脲 | 4559-87-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-甲基-1-苯基脲
• 英文名称: 1-methyl-1-phenylurea
• 英文别名: carbamyl methyl aniline
• CAS: 4559-87-9
• 化学式: C₈H₁₀N₂O
• mdl: MFCD00456415
• 分子量: 150.18
• InChiKey: SKAADKSETAYKGL-UHFFFAOYSA-N

物化性质

• 熔点：
  82 °C
• 沸点：
  257.6±23.0 °C(Predicted)
• 密度：
  1.171±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  1-甲基-1-苯基脲 在 溶剂黄146 作用下， 以 苯 为溶剂， 反应 7.0h， 生成 1-acetyl-3a-(2',5'-dioxo-3'-pyrrolidinyl)-1-methyl-3-methylphenylamino-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-4,5-dione
  参考文献：
  名称：

  N，N-二取代的2-氨基恶唑与马来酰亚胺反应中杂二烯合成和1,3-环加成反应的产物

  摘要：

  DOI：

  10.1007/bf02290850
• 作为产物：
  描述：

  methyl(phenyl)cyanamide 在 盐酸 作用下， 生成 1-甲基-1-苯基脲
  参考文献：
  名称：

  Malik, Abdul; Afza, Nighat; Siddiqui, Salimuzzaman, Zeitschrift fur Naturforschung, Teil B: Anorganische Chemie, Organische Chemie, 1982, vol. 37, # 4, p. 512 - 518

  摘要：

  DOI：

文献信息

• First Synthesis of Highly Chemiluminescent Benzo[<i>b</i>]furan‐2(3<i>H</i>)‐ones Bearing a Urea Substructure
  作者：Reimar Krieg、Birgit Hoffmann、Dieter Weiß、Christoph Biskup

  DOI：10.1002/hlca.201800243

  日期：2019.6

  A series of benzo[b]furan‐2(3H)‐ones (coumaran‐2‐ones) bearing a urea substructure, namely derivatives of 3‐(aminocarbonylamino)benzo[b]furan‐2(3H)‐one, was prepared for the first time. The accessibility of these compounds through an electrophilic α‐amidoalkylation approach of phenols (Tscherniac–Einhorn reaction) in the key step as well as the chemiluminescence (CL) properties of the desired compounds

  一系列带有脲亚结构的苯并[ b ]呋喃-2（3 H）-ones（coumaran-2-ones），即3-（氨基羰基氨基）苯并[ b ]呋喃-2（3 H）-one的衍生物，是第一次准备。这些化合物在关键步骤中通过酚类的亲电α氨基烷基化方法（Tscherniac-Einhorn反应）的可及性以及所需化合物的化学发光（CL）性能在很大程度上取决于尿素部分的取代方式。讨论了竞争性的反应途径，并提出了一种具有普遍意义的改进的一锅法合成方法。总之，尤其是N，苯并[ b ]呋喃-2（3 H）-的N-二烷基氨基羰基氨基衍生物在用1,8-二氮杂双环[5.4.0]十一碳-7-烯（DBU）处理后表现出强烈的闪光，如蓝色CL在氧气或过氧化氢的存在下。比较的物理化学研究表明，就CL强度和衰变速度而言，新化合物的性能优于其氨基甲酸酯类似物，这使其有可能在短时间内用作基于CL的新工具。
• [EN] FUSED QUINOLINE DERIVATIVE AND USE THEREOF<br/>[FR] DÉRIVÉ DE QUINOLINE FUSIONNÉE ET UTILISATION DE CELUI-CI
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2005105802A1

  公开（公告）日：2005-11-10

  The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein Rl is a hydrogen atom and the like; R2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R4 and R5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R6 is (cyclic group optionally having substituent(s)) -carbonyl, and the like; R7, R8, R9 and R10 are the same or different and each is a hydrogen atom, halogen and the like; or R7 and R8, R8 and R9, and R9 and R10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; --- represents unsubstituted (i.e., absence) or a single bond; and --- represents a single bond or a double bond, or a salt thereof, and the like.

  本发明旨在提供一种具有神经激肽2（NK2）受体拮抗作用的喹啉衍生物，并涉及一种由式（I）表示的化合物，其中R1是氢原子等；R2是氢原子，可选地具有取代基的碳氢基团等；R3是未取代的（即缺失），氢原子等；R4和R5相同或不同，每个是氢原子，可选地具有取代基的碳氢基团等；R6是（环状基团，可选地具有取代基）-羰基等；R7、R8、R9和R10相同或不同，每个是氢原子，卤素等；或R7和R8、R8和R9、以及R9和R10可以与相邻的碳原子一起形成环；n是1到5的整数；---表示未取代的（即缺失）或单键；---表示单键或双键，或其盐等。
• A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG
  申请人：Shionogi & Co., Ltd.

  公开号：US20200261481A1

  公开（公告）日：2020-08-20

  A medicament characterized in that (A) a compound represented by the formula (I): its pharmaceutically acceptable salt, or a solvate thereof, wherein P is hydrogen or a group to form a prodrug; A 1 is CR 1A R 1B , S or O; A 2 is CR 2A R 2B , S or O; A 3 is CR 3A R 3B , S or O; A 4 is each independently CR 4A R 4B , S or O; the number of hetero atoms among atoms constituting the ring which consists of A 1 , A 2 , A 3 , A 4 , nitrogen atom adjacent to A 1 and carbon atom adjacent to A 4 is 1 or 2; R 1A and R 1B are each independently hydrogen, halogen, alkyl or the like; R 2A and R 2B are each independently hydrogen, halogen, alkyl, or the like; R 3A and R 3B are each independently hydrogen, halogen, alkyl, or the like; R 4A are each independently hydrogen, halogen, alkyl, or the like; R 4B are each independently hydrogen, halogen, alkyl, or the like; R 3A and R 3B may be taken together with an adjacent carbon atom to form non-aromatic carbocycle or non-aromatic heterocycle; n is any integer of 1 to 2; and R 1 is or the like, is combined with (B) compound(s) having an anti-influenza activity, its pharmaceutically acceptable salt or a solvate thereof and/or an antibody having anti-influenza activity, is useful for treating or preventing influenza.

  一种药物，其特征在于（A）由以下式（I）表示的化合物： 其药学上可接受的盐，或其溶剂合物， 其中 P为氢或形成前药的基团; A 1 为CR 1A R 1B 、S或O; A 2 为CR 2A R 2B 、S或O; A 3 为CR 3A R 3B 、S或O; A 4 分别为独立的CR 4A R 4B 、S或O; 构成由A 1 、A 2 、A 3 、A 4 、邻接到A 1 的氮原子和邻接到A 4 的碳原子的环的原子中的杂原子数为1或2; R 1A 和R 1B 分别为独立的氢、卤素、烷基或类似物; R 2A 和R 2B 分别为独立的氢、卤素、烷基或类似物; R 3A 和R 3B 分别为独立的氢、卤素、烷基或类似物; R 4A 分别为独立的氢、卤素、烷基或类似物; R 4B 分别为独立的氢、卤素、烷基或类似物; R 3A 和R 3B 可以与相邻的碳原子结合形成非芳香碳环或非芳香杂环; n为1到2的任意整数; 和 R 1 为 或类似物， 与具有抗流感活性的（B）化合物，其药学上可接受的盐或其溶剂合物和/或具有抗流感活性的抗体结合，用于治疗或预防流感。
• An efficient synthesis of 1,1-disubstituted hydrazines.
  作者：YASUOKI MURAKAMI、YUUSAKU YOKOYAMA、CHIYOKO SASAKURA、MAKIKO TAMAGAWA

  DOI：10.1248/cpb.31.423

  日期：——

  1, 1-Disubstituted hydrazines were prepared from the corresponding 1, 1-disubstituted ureas by means of the Hofmann rearrangement reaction. The yields were fairly good, except from the ureas susceptible to oxidation, and thus the present method represents an additional and efficient procedure for the synthesis of 1, 1-disubstituted hydrazines.

  通过Hofmann重排反应，从相应的1,1-二取代脲制备了1,1-二取代肼。除易被氧化脲外，产率相当好，因此本方法为1,1-二取代肼的合成提供了一种额外且高效的途径。
• Modified amino acids, pharmaceuticals containing these compounds and method for their production
  申请人：——

  公开号：US20010036946A1

  公开（公告）日：2001-11-01

  The present invention relates to modified amino acids of general formula 1 wherein A, Z, X, n, m, R, R 2 , R 3 , R 4 and R 11 are defined as in claims 1 to 5 , their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

  本发明涉及一般式1的改良氨基酸，其中A、Z、X、n、m、R、R2、R3、R4和R11如权利要求1至5中所定义，它们的互变异构体、对映异构体、混合物及其盐，特别是其与无机或有机酸或碱的生理上可接受的盐，含有这些化合物的药物组合物，其用途以及用于制备它们的过程，以及它们在抗体的生产和纯化中的用途，以及在RIA和ELISA测定中作为标记化合物以及在神经递质研究中作为诊断或分析辅助工具的用途。